Literature DB >> 3486694

CRF-induced seizures and behavior: interaction with amygdala kindling.

S R Weiss, R M Post, P W Gold, G Chrousos, T L Sullivan, D Walker, A Pert.   

Abstract

Intracerebroventricular (i.c.v.) administration of ovine corticotropin-releasing factor (CRF) in doses varying from 10 to 100 micrograms has been reported to produce the late onset of seizures that resemble those observed during electrical kindling of the amygdala. We assessed the effects of repeated CRF administration on seizure development and on subsequent electrical kindling of the amygdala. Rats were administered vehicle or CRF (100 micrograms in 10 microliter of sterile water, i.c.v.) once daily for 5 consecutive days and were rated for seizures and aggressive behavior. On days 1 or 2, all animals receiving CRF developed major motor seizures of late onset (1-5 h post-injection), accompanied by spiking in the amygdala. By day 5, however, no rats had seizures, suggesting the development of tolerance. Defensive biting attacks were also observed following latencies of several hours and tolerance appeared to develop to these as well. After the CRF regimen, treated rats developed amygdala-kindled seizures following electrical stimulation approximately twice as fast as vehicle-injected controls (P less than 0.03). In a second experiment, rats were electrically kindled or sham-kindled prior to receiving i.c.v. CRF (100 micrograms). Kindled animals were significantly less sensitive to the seizure-inducing effects of CRF (P less than 0.03), but were more intensely aggressive than sham-kindled animals or naive rats receiving CRF for the first time.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3486694     DOI: 10.1016/0006-8993(86)91142-x

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  18 in total

1.  How does metyrapone decrease seizures?

Authors:  C A Koch; S R Bornstein; K Pacak; G P Chrousos
Journal:  Neurosurg Rev       Date:  1998       Impact factor: 3.042

2.  A functional continuum of regulatory anxiety-enhancing peptides. The search for complexes providing the optimal basis for developing inhibitory therapeutic agents.

Authors:  S V Koroleva; I P Ashmarin
Journal:  Neurosci Behav Physiol       Date:  2006-02

Review 3.  The biological effects of childhood trauma.

Authors:  Michael D De Bellis; Abigail Zisk
Journal:  Child Adolesc Psychiatr Clin N Am       Date:  2014-02-16

Review 4.  Psychiatric implications of altered limbic-hypothalamic-pituitary-adrenocortical activity.

Authors:  F Holsboer
Journal:  Eur Arch Psychiatry Neurol Sci       Date:  1989

5.  Time- and dose-dependent effects of corticotropin releasing factor on cerebral glucose metabolism in rats.

Authors:  U Freo; C Ori; S R B Weiss; G I Perini
Journal:  J Neural Transm (Vienna)       Date:  2005-04-22       Impact factor: 3.575

Review 6.  Neuropeptide-mediated excitability: a key triggering mechanism for seizure generation in the developing brain.

Authors:  T Z Baram; C G Hatalski
Journal:  Trends Neurosci       Date:  1998-11       Impact factor: 13.837

7.  The effects of corticotrophin-releasing factor and two antagonists on breathing movements in fetal sheep.

Authors:  L Bennet; B M Johnston; W W Vale; P D Gluckman
Journal:  J Physiol       Date:  1990-02       Impact factor: 5.182

8.  The in vivo proconvulsant effects of corticotropin releasing hormone in the developing rat are independent of ionotropic glutamate receptor activation.

Authors:  K L Brunson; L Schultz; T Z Baram
Journal:  Brain Res Dev Brain Res       Date:  1998-11-01

Review 9.  Neonatal and Infantile Epilepsy: Acquired and Genetic Models.

Authors:  Aristea S Galanopoulou; Solomon L Moshé
Journal:  Cold Spring Harb Perspect Med       Date:  2015-12-04       Impact factor: 6.915

10.  Early life stress as an influence on limbic epilepsy: an hypothesis whose time has come?

Authors:  Amelia S Koe; Nigel C Jones; Michael R Salzberg
Journal:  Front Behav Neurosci       Date:  2009-10-05       Impact factor: 3.558

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.